ACADIA Pharmaceuticals Inc (ACAD)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 258,075 | 136,693 | 45,744 | 14,905 | -51,036 | -131,629 | -105,901 | -145,812 | -213,444 | -215,459 | -203,833 | -213,663 | -167,519 | -190,957 | -261,027 | -259,377 | -280,973 | -267,266 | -224,649 | -237,477 |
| Revenue (ttm) | US$ in thousands | 957,797 | 929,236 | 890,534 | 813,806 | 726,437 | 631,886 | 550,901 | 520,229 | 517,235 | 511,503 | 512,401 | 493,059 | 484,145 | 474,394 | 463,359 | 458,241 | 441,755 | 419,074 | 393,083 | 366,185 |
| Pretax margin | 26.94% | 14.71% | 5.14% | 1.83% | -7.03% | -20.83% | -19.22% | -28.03% | -41.27% | -42.12% | -39.78% | -43.33% | -34.60% | -40.25% | -56.33% | -56.60% | -63.60% | -63.78% | -57.15% | -64.85% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $258,075K ÷ $957,797K
= 26.94%
ACADIA Pharmaceuticals Inc's pretax margin experienced a notable improvement over the past few quarters. The pretax margin was negative, ranging from -64.85% to -56.33% in the first half of 2021. However, from September 2021 to December 2024, the pretax margin showed a positive trend, increasing steadily from -40.25% to 26.94%. This positive momentum indicates that the company has been able to control its expenses and generate higher earnings before taxes relative to its revenue in recent quarters. Investors and stakeholders may view this improvement positively as it could signal better financial health and operational efficiency for ACADIA Pharmaceuticals Inc.
Peer comparison
Dec 31, 2024